Municipal Employees Retirement System of Michigan increased its holdings in Emergent Biosolutions, Inc. (NYSE:EBS) by 61.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,180 shares of the biopharmaceutical company’s stock after acquiring an additional 5,020 shares during the period. Municipal Employees Retirement System of Michigan’s holdings in Emergent Biosolutions were worth $533,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of EBS. Sei Investments Co. increased its stake in Emergent Biosolutions by 97,546.2% in the 2nd quarter. Sei Investments Co. now owns 38,082 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 38,043 shares during the last quarter. Federated Investors Inc. PA increased its stake in Emergent Biosolutions by 3.4% in the 2nd quarter. Federated Investors Inc. PA now owns 245,002 shares of the biopharmaceutical company’s stock valued at $8,308,000 after buying an additional 8,098 shares during the last quarter. New Amsterdam Partners LLC NY increased its stake in Emergent Biosolutions by 66.3% in the 3rd quarter. New Amsterdam Partners LLC NY now owns 163,337 shares of the biopharmaceutical company’s stock valued at $6,607,000 after buying an additional 65,109 shares during the last quarter. First Trust Advisors LP increased its stake in Emergent Biosolutions by 169.2% in the 2nd quarter. First Trust Advisors LP now owns 53,149 shares of the biopharmaceutical company’s stock valued at $1,802,000 after buying an additional 33,403 shares during the last quarter. Finally, Piedmont Investment Advisors LLC purchased a new stake in Emergent Biosolutions in the 2nd quarter valued at about $255,000. Institutional investors own 92.70% of the company’s stock.

In other news, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total transaction of $1,347,597.16. Following the completion of the transaction, the chief executive officer now directly owns 215,642 shares of the company’s stock, valued at approximately $9,223,008.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Fuad El-Hibri sold 47,983 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total transaction of $2,009,528.04. Following the transaction, the chairman now directly owns 1,550,216 shares of the company’s stock, valued at $64,923,046.08. The disclosure for this sale can be found here. Insiders have sold a total of 279,632 shares of company stock valued at $11,288,315 over the last three months. Insiders own 16.50% of the company’s stock.

EBS has been the subject of several analyst reports. BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “hold” rating to a “strong-buy” rating and set a $48.00 price objective for the company in a research note on Tuesday, November 28th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $46.00.

Shares of Emergent Biosolutions, Inc. (NYSE:EBS) opened at $43.86 on Tuesday. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. The company has a market cap of $1,815.19, a PE ratio of 23.20, a price-to-earnings-growth ratio of 1.21 and a beta of 1.24. Emergent Biosolutions, Inc. has a one year low of $26.16 and a one year high of $44.97.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The firm had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. During the same period in the prior year, the firm earned $0.56 EPS. The company’s revenue was up 4.6% compared to the same quarter last year. equities research analysts forecast that Emergent Biosolutions, Inc. will post 1.64 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Municipal Employees Retirement System of Michigan Has $533,000 Position in Emergent Biosolutions, Inc. (EBS)” was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/municipal-employees-retirement-system-of-michigan-has-533000-position-in-emergent-biosolutions-inc-ebs/1745146.html.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.